[Effect of peroxisome proliferator-activated receptor-alpha agonist on adipokines expression in rats fed with high-fat diet].
OBJECTIVE
To explore the effect of peroxisome proliferator-activated receptor-alpha ( PPAR-alpha) agonist fenofibrate on adipokines expression in high-fat diet fed SD rats and its relationship to insulin resistance (IR).


METHODS
Rats were randomized into three groups (n = 10) : HD group, fed with high-fat diet; HDF group, fed with high fat diet and treated with fenofibrate; and control group, fed with normal diet. Animals were sacrificed after 4-week follow-up. Plasma lipids, fasting plasma insulin, free fatty acids (FFA), and insulin sensitivity were detected. Reverse transcription-polymerase chain reaction was used to semi-quantitatively determine the mRNA expression of adipokines including tumor necrosis factor-alpha (TNF-alpha) , interleukin-6 (IL-6), angiotensinogen (AGT), angiotensin 11 type 1 receptor (AT1R), and adiponectin in brown fat.


RESULTS
The plasma level of FFA, TG, and homeostatic model approach-IR index were (2. 37+/-0. 60) vs (1. 59+/-0. 30) vs (1. 33+/-0. 34 ) mmol/L, (0. 48+/-0. 11) vs (0. 30+/-0. 04) vs (0. 36+/-0. 07) mmol/L, and 12. 30+/-3. 97 vs 5. 03 +/-1. 88 vs 4. 17+/-1. 27 in the HD group, HDF group, and control group after 4 weeks of treatment with fenofibrate, respectively. The mRNA expressions of TNF-alpha and adiponectin were 1. 726+/-1. 408 vs 0. 713+/-0. 711 vs 0. 593+/-0. 382 and 0. 660+/-0. 192 vs 0. 949+/-0. 35 vs 0. 936+/-0. 130 in these three groups, which showed significant difference between HD group and HDF group (P < 0. 05 ) , while no significant difference between HDF group and control group (P > 0. 05). The mRNA expressions of AGT, AT1 R, and IL-6 had no significant difference among these three groups (P > 0. 05 ).


CONCLUSIONS
PPAR-alpha agonist fenofibrate may reverse high-fat diet induced lipid abnormalities, improve insulin sensitivity, and regulate the mRNA expressions of TNF-alpha and adiponectin in adipose tissues.
Li
Yan
Y
Department of Endocrinology, The Second Affiliated Hospital of Sun Yat-sen University, Guangzhou 510120, China. liyan19642002@yahoo.com
Huang
Bin
B
Cheng
Hua
H
Liang
Zhen
Z
Liu
Shan-ying
SY
D052242:Adiponectin / Q000096:biosynthesis; D000273:Adipose Tissue / Q000187:drug effects / Q000378:metabolism*; D000809:Angiotensins / Q000096:biosynthesis; D000818:Animals; D004041:Dietary Fats / Q000009:adverse effects; D004195:Disease Models, Animal; D011345:Fenofibrate / Q000494:pharmacology*; D007333:Insulin Resistance; D015850:Interleukin-6 / Q000096:biosynthesis; D008062:Lipofuscin / Q000096:biosynthesis*; D008297:Male; D047493:PPAR alpha / Q000037:antagonists & inhibitors*; D012333:RNA, Messenger / Q000096:biosynthesis; D051381:Rats; D017207:Rats, Sprague-Dawley; D044139:Receptor, Angiotensin, Type 2 / Q000096:biosynthesis; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis*
D052242:Adiponectin; D000809:Angiotensins; D004041:Dietary Fats; D015850:Interleukin-6; D008062:Lipofuscin; D047493:PPAR alpha; D012333:RNA, Messenger; D044139:Receptor, Angiotensin, Type 2; D014409:Tumor Necrosis Factor-alpha; D011345:Fenofibrate